Skip to main content
. Author manuscript; available in PMC: 2020 Oct 11.
Published in final edited form as: ACS Infect Dis. 2019 Aug 14;5(10):1738–1753. doi: 10.1021/acsinfecdis.9b00168

Figure 5.

Figure 5.

Interference Frequency Index (IFI) as a function of the compound pEC50 value for the 966 compounds that had sufficient potency to allow calculation of the EC50 values. Blue box indicates hits with IFI < 0.05. IFI measures the frequency that a compound is found to be a robust active in multiple HTS campaigns (i.e., the number of times a compound is found to be a robust active hit divided by the number of times it has been screened in HTS campaigns at GlaxoSmithKline).